You will be shown inclusion or exclusion criteria for a clinical trial. Given these criteria, your task is to extract all unique entities of the following types: ["Observation", "Condition", "Procedure", "Drug", "Temporal", "Multiplier", "Qualifier", "Negation", "ReferencePoint", "Scope", "Value", "Mood", "Device", "Visit", "Measurement", "Person"].

Please return the output as a JSON object of the format: {"Condition" : ["breast cancer", ...], "Device" : ["ports", ...], "Drug" : ["Atenolol", ...], "Measurement" : ["blood pressure", ...], "Mood" : ["suspected", ...], "Multiplier" : ["more than two", ...], "Negation" : ["no", ...], "Observation" : ["history", ...], "Person" : ["male", ...], "Procedure" : ["surgery", ...], "Qualifier" : ["severe", ...], "ReferencePoint" : ["enrollment", ...], "Scope" : ["infection", ...], "Temporal" : ["one day", ...], "Value" : ["50%", ...], "Visit" : ["ICU", ...]}. The keys should be entity types and values should be lists of extracted entities belonging to the corresponding type. If you cannot find entities belonging to a specific type, the value should be [].

Only output the JSON object and do not include any additional text.

Abstract:

Known or suspected alcohol or substance abuse in the preceding 12 months.
Women who are pregnant or breastfeeding.
Women of childbearing potential (WOCP) who are not using at least one method of contraception.
Patients with severe renal impairment (CLcr = 29 mL/min, or eGFR = 29 mL/min/1.73 m2), or moderate or severe hepatic impairment (Child-Pugh classes B or C).
Patients with bladder outlet obstruction (BOO) that, in the opinion of the study urologist, would expose them to risk of urinary retention during treatment with mirabegron.
Patients treated with drugs metabolized by the CYP2D6 pathway.
Patients with supine systolic blood pressure (SBP) = 180 mm Hg, or diastolic blood pressure (DBP) = 110 mm Hg.
Clinically significant, uncontrolled cardiac arrhythmia, unstable angina, congestive heart failure (NYHA Class 3 or 4), or history of myocardial infarction in the preceding 2 years.
History of cancer in the preceding 2 years other than successfully treated, non-metastatic, squamous cell or basal cell carcinoma, or cervical cancer in situ.
Any major urological procedure in the preceding 90 days.
Any major surgical procedure in the preceding 30 days.
Previously treated with mirabegron within 60 days prior to the baseline visit (Visit 2), or previously having failed treatment with mirabegron regardless of duration and timing of treatment.
Current or previous, within the 60 days preceding the baseline visit (Visit 2), treatment with antimuscarinic agents for OAB symptoms; and, willingness to not use antimuscarinic agents for the duration of the study.
Currently receiving any other investigational drug or having received an investigational drug within the 60 days preceding the baseline visit (Visit 2).
Any condition or laboratory test result, which, in the opinion of the Investigator or the Study Urologist, might result in an increased risk to the patient, or would affect their participation in the study.
Any patient who, in the opinion of the Investigator, is not a good candidate for the study or will not be able to follow study procedures.
{"Condition": ["hepatic impairment", "renal impairment", "cancer", "substance abuse", "cardiac arrhythmia", "basal cell carcinoma", "BOO", "bladder outlet obstruction", "unstable angina", "cervical cancer in situ", "a, or cer  cell or bas", "myocardial infarction", "OAB symptoms", "congestive heart failure", "alcohol abuse"], "Device": [], "Drug": ["mirabegron", "antimuscarinic agents"], "Measurement": ["SBP", "NYHA Class", "systolic blood pressure", "DBP", "CLcr", "eGFR", "diastolic blood pressure", "Child-Pugh classes"], "Mood": [], "Multiplier": [], "Negation": ["other"], "Observation": ["risk of urinary retention"], "Person": [], "Procedure": ["major urological procedure", "major surgical procedure"], "Qualifier": ["supine", "severe", "moderate", "successfully treated", "non-metastatic", "uncontrolled"], "ReferencePoint": ["baseline visit"], "Scope": ["3 or 4", "moderate or severe", "B or C", "alcohol or substance abuse", "squamous cell or basal cell carcinoma, or cervical cancer in situ", "CLcr = 29 mL/min, or eGFR = 29 mL/min/1.73 m2"], "Temporal": ["within 60 days prior to the baseline visit", "within the 60 days preceding the baseline visit", "preceding 30 days", "preceding 12 months", "preceding 90 days", "preceding 2 years"], "Value": ["= 29 mL/min/1.73 m2", "3", "= 180 mm Hg", "= 110 mm Hg", "4", "B", "= 29 mL/min", "C"], "Visit": []}